Express News | Viracta Therapeutics Inc - Receives Notice of Non-Compliance From Nasdaq

ReutersNov 22 17:21 ET

Viracta Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesNov 14 12:18 ET · Ratings

RBC Cuts Price Target on Viracta Therapeutics to $2 From $4, Keeps Outperform, Speculative Risk

MT NewswiresNov 14 07:40 ET · Ratings

Viracta Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 13 16:36 ET · Announcements

Viracta Therapeutics | 8-K: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

SECNov 13 07:33 ET

Viracta Therapeutics Reports Q3 EPS (27c) Vs (33c) Last Year

TipRanksNov 13 07:17 ET